AKT1 and rheumatoid arthritis: Based on the results from previous reports [11–13] and our RNA-seq results (Supplementary Figure 4), we identified the PI3K/AKT pathway as a potential downstream target of the tocilizumab-MIR31HG-miR-214-PTEN axis in RA-FLS.